Trials / Active Not Recruiting
Active Not RecruitingNCT06715124
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 237 (estimated)
- Sponsor
- Quanta Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QTX3544 | QTX3544 will be administered at protocol defined dose. |
| COMBINATION_PRODUCT | Cetuximab | Cetuximab will be administered at protocol defined dose. |
Timeline
- Start date
- 2025-01-14
- Primary completion
- 2027-01-02
- Completion
- 2029-01-02
- First posted
- 2024-12-04
- Last updated
- 2026-03-02
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06715124. Inclusion in this directory is not an endorsement.